<DOC>
	<DOCNO>NCT00117286</DOCNO>
	<brief_summary>This extension study study FE200486 CS14 ( NCT00116779 ) . Each participant treat discontinue withdrawn study , marketing authorization degarelix obtain . The study terminate ongoing participant treat least 5 year .</brief_summary>
	<brief_title>Extension Study Investigating Long-Term Safety Degarelix One-Month Depots Patients With Prostate Cancer</brief_title>
	<detailed_description>Participants complete main FE200486 CS14 study initially continue dose FE200486 CS14A extension study . A protocol amendment change dosage 160 mg ( 40 mg/mL ) study participant . The data include data participant participate main study ( FE200486 CS14 ; NCT00116779 ) extension study FE200486 CS14A .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Has give write consent prior studyrelated activity perform . A studyrelated activity define procedure would perform normal management patient . Has complete study FE200486 CS14 visit 22 . Exclusion Criterion : Has withdraw FE200486 CS14 study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Androgen ablation therapy</keyword>
</DOC>